tiprankstipranks
Trending News
More News >

Nurix Therapeutics price target lowered to $25 from $32 at Wells Fargo

Wells Fargo analyst Derek Archila lowered the firm’s price target on Nurix Therapeutics (NRIX) to $25 from $32 and keeps an Overweight rating on the shares. The firm views bexobrutideg as highly de-risked in CLL and thinks regulatory updates and initiation of pivotal trials are modest catalysts in 2025. With shares approaching 52-week lows, it offers an attractive entry point for long-term investors, Wells adds.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue